Key Takeaways
- Bowel (colorectal) cancer is increasingly diagnosed in Australians under 50, with a 137 % rise in the 30‑39 age group since 2000.
- Genomic profiling through initiatives like Omico reveals that about one‑third of bowel‑cancer patients are under 50, and roughly one‑sixth have MSI‑high tumours that respond exceptionally well to immunotherapy.
- Nathan Borg, a 29‑year‑old project manager, was diagnosed with MSI‑high bowel cancer linked to Lynch syndrome; immunotherapy (pembrolizumab) led to disease‑free status after surgery, chemotherapy, and radiotherapy.
- Experts stress the need to lower the threshold for investigating gastrointestinal symptoms in young people and call for more research into environmental, dietary, and genetic contributors to early‑onset disease.
- Recent funding ($15 million) from Cancer Australia and the NHMRC will support seven research projects, three focused on colorectal cancer, to improve risk‑factor understanding, testing, and treatment options.
Patient Story: Nathan Borg’s Diagnosis
Nathan Borg was still groggy from anaesthesia when his doctor informed him he had bowel cancer. At 29, he was just three months away from his wedding to Samantha, who sat beside him in tears. Borg had assumed the blood in his stool was due to haemorrhoids after purchasing a house, taking on a mortgage, and planning his marriage. The diagnosis came as a complete shock, underscoring how quickly a routine symptom can escalate into a life‑changing cancer alert for young adults.
Rising Incidence of Early‑Onset Bowel Cancer
Data show a steep increase in bowel‑cancer cases among Australians in their 30s, up 137 % since 2000. Although the absolute numbers remain modest—rising from 184 cases in 2000 to an estimated 772 in 2025 for the 30‑39 cohort—the trend signals a shift in disease epidemiology. Almost 14 % of bowel‑cancer patients in a large genomic cohort are under 40, and 2 % are under 30, highlighting that colorectal cancer can no longer be regarded solely as an illness of older adults.
Genomic Insights from the Omico Initiative
Omico, a program that facilitates comprehensive genomic profiling for patients with poor prognoses, analysed a cohort of bowel‑cancer patients and found that 34 % were under 50, compared with 23.5 % across all other cancers. Nearly 80 % of bowel‑cancer participants received a matched treatment recommendation, and one in five enrolled in a clinical trial or accessed the therapy they were matched to after profiling. These figures illustrate how genomic testing can uncover actionable targets in younger patients who might otherwise be considered too advanced for standard approaches.
MSI‑High Tumours and Immunotherapy Sensitivity
A subset—about one in six—of bowel‑cancer tumours exhibits microsatellite instability (MSI), a genomic quirk where DNA mismatch‑repair proteins fail to correct errors in short repeats. MSI‑high tumours are “exquisitely sensitive” to immune checkpoint inhibitors, according to leading precision‑oncology experts. In Nathan Borg’s case, Omico’s testing revealed an MSI‑high status, opening the door to immunotherapy after conventional treatments had begun.
Link to Lynch Syndrome
Further genomic work‑up identified Lynch syndrome in Borg, an inherited condition responsible for roughly 3 % of MSI‑related colorectal cancers. Lynch syndrome predisposes individuals to early‑onset gastrointestinal malignancies and necessitates surveillance for relatives. Borg’s diagnosis highlighted how a hereditary component can coexist with spontaneous MSI, prompting clinicians to consider genetic counselling even when a tumour appears sporadic.
Treatment Journey: Surgery, Chemo, Radiation, and Immunotherapy
Borg’s treatment plan was intensive: neoadjuvant radiation and chemotherapy to shrink a six‑centimetre tumour, followed by resection of 30 centimetres of bowel and a six‑month period living with a stoma. He endured hair loss, fatigue, and the typical side‑effects of chemo while balancing a mortgage and imminent wedding. When metastatic spots appeared in his liver, his oncologist, guided by the MSI‑high result, switched him to pembrolizumab, a PD‑1 inhibitor funded through the Pharmaceutical Benefits Scheme. Borg tolerated the two‑year immunotherapy course well and has been cancer‑free since January 2024.
Personal Impact and Outlook
Despite the gruelling regimen, Borg and Samantha proceeded with their wedding three months after diagnosis and are now expecting their first child in August 2024. Borg reflects that he always believed he would overcome the disease, crediting the immunotherapy breakthrough as a “game‑changer.” His story exemplifies how timely genomic identification can transform a dire prognosis into a hopeful future for young patients facing aggressive cancers.
Expert Perspectives on Causality and Screening
David Thomas, founder and chief scientist of Omico, cautions that the rise in early‑onset colorectal cancer cannot be ascribed to genetics alone; environmental exposures, diet, or microplastics may play roles. He urges the medical community to investigate why incidence is climbing. Dorothy Keefe, CEO of Cancer Australia, argues against lowering the national bowel‑cancer screening age universally, citing cost, potential harm from false positives, and colonoscopy wait‑list burdens. Instead, she advocates heightened vigilance: young people should consult GPs for persistent rectal bleeding, altered bowel habits, unexplained weight loss, fatigue, or low haemoglobin.
Research Funding and Future Directions
Recognising the urgency, Cancer Australia and the National Health and Medical Research Council have allocated $15 million to fund seven research projects examining early‑onset cancer risk factors, diagnostics, and therapeutics. Three of these projects will focus specifically on colorectal cancer, aiming to uncover mechanistic links, improve risk‑prediction models, and refine screening strategies for younger populations. The investment reflects a national commitment to shifting from reactive treatment to proactive prevention.
Implications for Clinical Practice
The convergence of rising case numbers, actionable MSI‑high biomarkers, and successful immunotherapy outcomes demands a re‑evaluation of how clinicians approach gastrointestinal symptoms in patients under 50. Routine MSI testing—already standard in many pathology labs—should be complemented by broader genomic profiling when initial therapies fail or when advanced disease is detected. Genetic counselling for Lynch syndrome and related hereditary syndromes becomes essential, not only for the index patient but also for at‑risk family members.
Conclusion
Nathan Borg’s experience encapsulates a shifting landscape: young Australians are confronting bowel cancer at increasing rates, yet advances in genomic medicine are unveiling vulnerabilities—such as MSI‑high status—that render tumours highly responsive to immunotherapy. Continued research, heightened clinical awareness, and targeted screening strategies will be vital to curb the tide of early‑onset colorectal cancer and improve outcomes for the next generation.